First trials test targeting of α-synuclein for Parkinson disease
Crossref DOI link: https://doi.org/10.1038/s41582-022-00726-6
Published Online: 2022-09-23
Published Print: 2022-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kalia, Lorraine V. http://orcid.org/0000-0002-9384-1305
Text and Data Mining valid from 2022-09-23
Version of Record valid from 2022-09-23
Article History
First Online: 23 September 2022
Competing interests
: L.V.K. has received consultation fees from AC Immune and UCB in the past year.